Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized multicenter study of arsenic trioxide versus Realgar-Indigo naturalis formula with ATRA and chemotherapy in childhood acute promyelocytic leukemia
ChiCTR-TRC-13004021Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2012
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of arsenic trioxide, Compound Huangdai Tablet and tretinoin in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 5-year event-free survival. Started May 2012; status: recruiting.
02
Drugs
arsenic trioxideCompound Huangdai Tablettretinoin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-TRC-13004021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004021.